FTC Renews Push to Remove Improper Drug Patents That Block Generics
The agency is challenging more than 200 patent listings it says were improperly used to keep prescription prices high. The Federal Trade Commission on May 21 escalated its efforts to lower prescription drug costs, renewing challenges to more than 200 patents it says were improperly listed to prevent generic versions of brand-name drugs from reaching